Werewolf Therapeutics ( (HOWL) ) has provided an update.
On February 19, 2025, Derek DiRocco, M.D., announced his resignation from the Board of Directors of Werewolf Therapeutics, effective at the company’s 2025 annual meeting of stockholders. His departure was not due to any disagreement with the company. Concurrently, Anil Singhal, Ph.D., was appointed as a new director and member of the Audit Committee. Dr. Singhal brings over three decades of experience in the biopharmaceutical industry, having previously led Trishula Therapeutics and Adicet Bio. His appointment is expected to strengthen Werewolf Therapeutics’ leadership and strategic direction, potentially impacting its market positioning and stakeholder interests.
More about Werewolf Therapeutics
Werewolf Therapeutics is a company operating in the biopharmaceutical industry, focusing on the development of innovative therapies. The company is involved in creating products aimed at treating various diseases, with a particular emphasis on oncology.
YTD Price Performance: -11.54%
Average Trading Volume: 310,785
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $61.5M
Learn more about HOWL stock on TipRanks’ Stock Analysis page.